ArticleGenomics & informatics2013
Somatic mutaome profile in human cancer tissues.
Article in Genomics & informatics, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 54 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
54 citing papers in PubMed, 80 citations in OpenAlex.
- Article
- Deciphering Deleterious nsSNPs in MUC16's SEA Domain: Structural and Functional Implications in Cancer Metastasis via Computational Analysis.Journal of cellular and molecular medicine · 2025Article
- Bioinformatics-based analysis of nicotinamide adenine dinucleotide metabolism-related genes to predict immune status and prognosis for head and neck squamous cell carcinoma patients.Frontiers in immunology · 2025Article
- Whole-exome sequencing reveals novel genomic signatures and potential therapeutic targets during the progression of rectal neuroendocrine neoplasm.Cell death & disease · 2024Article
- Article
- A Comprehensive Analysis of HOXB13 Expression in Hepatocellular Carcinoma.Medicina (Kaunas, Lithuania) · 2024Article
- Article
- The prognostic value of tumor mutation burden (TMB) and its relationship with immune infiltration in breast cancer patients.European journal of medical research · 2023Article
- Heterogeneous pattern of gene expression driven byFrontiers in oncology · 2023Article
- Engineering of a Fully Human Anti-MUC-16 Antibody and Evaluation as a PET Imaging Agent.Pharmaceutics · 2022Article
- LINC02126 is a potential diagnostic, prognostic and immunotherapeutic target for lung adenocarcinoma.BMC pulmonary medicine · 2022Article
- [MUC16: The Novel Target for Tumor Therapy].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2022Review
- Development and verification of a microsatellite instability-related risk signature for predicting survival and therapy effectiveness in gastric cancer.Journal of gastrointestinal oncology · 2022Article
- The Identification of Two RNA Modification Patterns and Tumor Microenvironment Infiltration Characterization of Lung Adenocarcinoma.Frontiers in genetics · 2022Article
- Effect ofAmerican journal of translational research · 2022Article
- Whole-Exome Sequencing in Papillary Microcarcinoma: Potential Early Biomarkers of Lateral Lymph Node Metastasis.Endocrinology and metabolism (Seoul, Korea) · 2021Article
- Novel genetic characteristics in low-grade fetal adenocarcinoma of the lung.Thoracic cancer · 2021Article
- Mucin in cancer: a stealth cloak for cancer cells.BMB reports · 2021Review
- Age-related differences of immune infiltrates in pheochromocytomas and paragangliomas.Journal of endocrinological investigation · 2021Article
- Predictive effects of preoperative serum CA125 and AFP levels on post-hepatectomy survival in patients with hepatitis B-related hepatocellular carcinoma.Oncology letters · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Somatic mutation is a major cause of cancer progression and varied responses of tumors against anticancer agents. Thus, we must obtain and characterize genome-wide mutational profiles in individual cancer subtypes. The Cancer Genome Atlas database includes large amounts of sequencing and omics data generated from diverse human cancer tissues. In the present study, we integrated and analyzed the exome sequencing data from ~3,000 tissue samples and summarized the major mutant genes in each of the diverse cancer subtypes and stages. Mutations were observed in most human genes (~23,000 genes) with low frequency from an analysis of 11 major cancer subtypes. The majority of tissue samples harbored 20-80 different mutant genes, on average. Lung cancer samples showed a greater number of mutations in diverse genes than other cancer subtypes. Only a few genes were mutated with over 5% frequency in tissue samples. Interestingly, mutation frequency was generally similar between non-metastatic and metastastic samples in most cancer subtypes. Among the 12 major mutations, the TP53, USH2A, TTN, and MUC16 genes were found to be frequent in most cancer types, while BRAF, FRG1B, PBRM1, and VHL showed lineage-specific mutation patterns. The present study provides a useful resource to understand the broad spectrum of mutation frequencies in various cancer types.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.